A randomised, double-blind, placebo-controlled trial to assess the effect of phosphate reduction with lanthanum carbonate on arterial compliance and vascular calcification in patients with chronic kidney disease stages 3-4 [ 2013 - 2018 ]

Also known as: IMPROVE-CKD Study: Impact of a phosphate binder on cardiovascular disease in Chronic Kidney Disease.

Research Grant

[Cite as]

Researchers: A/Pr Carmel Hawley (Principal investigator) ,  A/Pr Eugenia Pedagogos A/Pr Grahame Elder A/Pr Nigel Toussaint Dr Geoffrey Block
View all 8 related researchers

Brief description Chronic kidney disease (CKD) is a significant health problem and is associated with an increased risk of cardiovascular (CV) disease. Vascular calcification and arterial stiffness (stiffening of the blood vessels and arteries) are very common in people with CKD, and are linked to increased death from CV events. This study aims to examine the ways in which treatment with a phosphate binder, Lanthanum Carbonate, may reduce vascular calcification and arterial stiffness to decrease CV events.

Funding Amount $AUD 1,668,664.33

Funding Scheme Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]